AbbVie Oncology Revenue Dips 3% as Imbruvica Sales Slide in Q1 2026

Key Facts

1ABBV's oncology revenues declined 3% in Q1 as Imbruvica sales experienced a slide.

2Venclexta, Elahere, and Epkinly posted solid gains despite overall portfolio headwinds.

In a move reflecting the mounting challenges within the biopharmaceutical sector, AbbVie reported mixed results for its oncology division during the first quarter of 2026. According to reports, oncology revenues declined by 3% primarily driven by a slide in sales for the blockbuster drug Imbruvica. However, the portfolio showed resilience as Venclexta, Elahere, and Epkinly posted solid gains, partially offsetting the broader headwinds faced by the segment.

This decline comes as major pharmaceutical players face intense competition from biosimilars, with partner Johnson & Johnson reporting similar pricing pressures in recent filings per market data. Compared to Q4 2025, these results highlight a strategic shift toward innovative therapies to counter the erosion of legacy product shares; analysts at Zacks Investment Research noted that Elahere's growth remains a critical catalyst following the ImmunoGen acquisition.

Traders should watch ABBV stock levels, which stood at $165.40 (close May 26, 2026), for signs of consolidation around key support levels. Looking ahead, upcoming US inflation data in the economic calendar could influence broader healthcare sector sentiment. Investors will also be focused on regulatory updates regarding the oncology pipeline at upcoming medical congresses to gauge the potential for a return to top-line growth.